Market Research Industry Reports

Breast Cancer [2017]: Bulletin #1

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS



Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from the Phase III APHINITY study of Perjeta (pertuzumab) as an adjuvant therapy for BC; Merck & Co. announcing data from the Keytruda (pembrolizumab) I-SPY 2 study; as well as the US approval and launch of Nerlynx (neratinib; Puma Biotechnology).



Business Questions:

How do KOLs regard Perjetas magnitude of benefit in the APHINITY trial?
According to KOLs, in which patients will Perjeta be prescribed?
What are KOLs views on Keytruda as a neoadjuvant therapy in triple-negative BC?
How do KOLs view checkpoint inhibitors in general as potential therapies for BC?
How do experts foresee Nerlynx being prescribed in the treatment of BC?
What factors, if any, are likely to impact Nerlynxs uptake?

USD 3500View Report

Global Breast X-Ray Machine Industry Market Research Report

The Breast X-Ray Machine market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR

USD 2960View Report

Breast Cancer: KOL Insight [2018]

How is biosimilar trastuzumab expected to fare in breast cancer Biosimilar trastuzumab is now available in Europe, and key opinion leaders (KOLs) weigh in on how this product is expected

USD 8495View Report

Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence

Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence Breast cancer is the second most common

USD 4995View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 1045
  • Enterprise Wide Licence    USD 2575
$ 1045

Reports Details

Published Date : Aug 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube